Safety of adeno-associated virus gene therapy vectors: a current evaluation

Author： Monahan Paul E   Jooss Karin   Sands Mark S  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.1, Iss.1, 2002-05, pp. : 79-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy

By  

Current Pharmaceutical Design, Vol. 21, Iss. 22, 2015-01 ,pp. : 3248-3256

Bentham Science Publishers

Access to resources Recommend Favorite

Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy

By  

Current Gene Therapy, Vol. 2, Iss. 4, 2002-01 ,pp. : 485-500

Bentham Science Publishers

Access to resources Recommend Favorite

Developing Immunologically Inert Adeno-Associated Virus (AAV) Vectors for Gene Therapy: Possibilities and Limitations

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 12, 2013-01 ,pp. : 1072-1082

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative Study of Adeno-associated Virus, Adenovirus, Bacu lovirus and Lentivirus Vectors for Gene Therapy of the Eyes

By  

Current Gene Therapy, Vol. 17, Iss. 3, 2017-12 ,pp. : 235-247

Bentham Science Publishers

Access to resources Recommend Favorite

Safety of adeno-associated viral vectors

By Lin Shih-Wen   Ertl Hildegund CJ  

Future Virology, Vol. 3, Iss. 5, 2008-09 ,pp. : 491-503

Future Medicine

Access to resources Recommend Favorite